NewAmsterdam Pharma (NAMS) Net Income towards Common Stockholders (2023 - 2026)

NewAmsterdam Pharma has reported Net Income towards Common Stockholders for 4 years, with the latest figure at -$48.4 million in Q1 2026.

• Quarterly Net Income towards Common Stockholders fell 22.55% year-over-year to -$48.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$212.7 million (down 13.54% YoY) and the FY2025 annual result came in at -$151.2 million, up 37.4% from the prior year.
• Net Income towards Common Stockholders grew to -$48.4 million in Q1 2026 per NAMS's latest filing, from -$74.9 million in the prior quarter.
• Over five years, Net Income towards Common Stockholders peaked at -$16.6 million in Q3 2024 and troughed at -$93.8 million in Q1 2024.
• A 4-year average of -$52.7 million and a median of -$47.8 million in 2023 frame the typical range for Net Income towards Common Stockholders.
• The sharpest annual moves came in 2024 and 2025: Net Income towards Common Stockholders surged 64.68% in 2024, then tumbled 332.54% in 2025.
• Over 4 years, Net Income towards Common Stockholders stood at -$49.5 million in 2023, then sank by 86.34% to -$92.2 million in 2024, then rose by 18.72% to -$74.9 million in 2025, then surged by 35.35% to -$48.4 million in 2026.
• According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered -$48.4 million, -$74.9 million, and -$72.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.